Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic

Plain-language summary

This study evaluated the use of OneOme RightMed®, a pharmacogenomic test applied before chemotherapy, in patients with colorectal cancer. It included patients aged 18 and older with histologically proven stage 2-4 colon or rectal adenocarcinoma who were planned for chemotherapy. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Essentia Health

Intervention

OneOme RightMed®

Start date

5/20/2017

Estimated completion

6/30/2019

Countries

United States

Related genes

Locations

• Duluth, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Histologically proven Stage 2-4 colon or rectal adenocarcinoma with an anticipated need for chemotherapy, which may include neoadjuvant, adjuvant or palliative treatment, and may include oral or intravenous chemotherapy.
2. Adequate organ function and performance status to receive chemotherapy as determined by the treating physician.
3. Age ≥ 18 years.
4. Ability to understand and the willingness to sign a written informed consent documented.
5. Patients must sign consent within 7 days of the physician visit for newly diagnosed or recurrent colorectal cancer when a patient is initially felt to be a candidate for chemotherapy.

Exclusion Criteria:

1. Patients received prior chemotherapy for colorectal cancer in the last 12 months.
2. Patients received prior OneOme RightMed® pharmacogenomic testing.